ABX464-902
30 evidence topics · 4 sources
Objective
Primary and secondary objectives in the protocol
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start (actual) | “2020-12-17” |
| Primary completion (actual) | “2021-05-18” |
Results reporting dates in the registry record
| Field | Registry entry |
|---|---|
| Results first submitted | “2022-05-06” |
| Results first posted | “2026-11-09” |
| Other study ID numbers | “ABX464-902” |
Single site in Wales, United Kingdom
Study design
Phase 1, two-part, fixed-sequence, open-label crossover design
Perpetrator and victim roles in each part
Rationale for the open-label design
Eligibility criteria
Key inclusion and exclusion criteria in the registry record
Treatment
Dose selection and administration with food
Study outcomes
Rationale for using caffeine and Obefazimod cmax and AUC as the primary endpoints
Registered primary and secondary outcomes
In vitro basis for a CYP1A2 interaction study
Choice of caffeine and fluvoxamine as probe drugs
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation in the protocol
Participants screened, enrolled, and analyzed
Description of analysis sets
Safety and pharmacokinetic sets in the protocol
Planned statistical comparison
Results
Participant disposition
Baseline characteristics
Age and sex by study part
| Characteristic | Part A (24 participants) | Part B (35 participants) |
|---|---|---|
| Age, mean (standard deviation), years | “33.7(9.44)” | “36.8(9.75)” |
| Sex, participants | “Part A Number Analyzed 24 participants Female 5 Male 19” | “Part B Number Analyzed 35 participants Female 13 Male 22” |
Race and ethnicity not collected
Efficacy results
Part A: caffeine exposure with and without obefazimod (PK analysis set, 22 participants)
| Measure, mean (standard deviation) | Day 1, caffeine alone | Day 4, caffeine and ABX464 | Day 17, caffeine and ABX464 |
|---|---|---|---|
| Caffeine Cmax, ng/mL | “931(285)” | “930(278)” | “564(242)” |
| Caffeine AUC, h*ng/mL | “7420(4760)” | “5460(2740)” | “1560(719)” |
Part B: obefazimod exposure with and without fluvoxamine (PK analysis set, 25 participants)
| Measure, mean (standard deviation) | Day 1, ABX464 alone | Day 11, ABX464 and fluvoxamine |
|---|---|---|
| ABX464 Cmax, ng/mL | “23.2(12.5)” | “33.4(19.0)” |
| ABX464 AUC, h*ng/mL | “55.2(25.7)” | “73.0(34.2)” |
Plain-language summary of the interaction results
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Adverse events, serious adverse events, and deaths
| Measure | Part A overall | Part B overall |
|---|---|---|
| Participants with any other (nonserious) adverse event | “16/24 (66.67%)” | “30/35 (85.71%)” |
| Participants with a serious adverse event | “0/24 (0.00%)” | “0/35 (0.00%)” |
Most frequent adverse events by study part
| Adverse event | Part A overall | Part B overall |
|---|---|---|
| Headache | “13/24 (54.17%)” | “25/35 (71.43%)” |
| Nausea | “7/24 (29.17%)” | “20/35 (57.14%)” |
| Vomiting | “2/24 (8.33%)” | “11/35 (31.43%)” |
| Decreased appetite | “1/24 (4.17%)” | “15/35 (42.86%)” |
| Fatigue | “3/24 (12.50%)” | “14/35 (40.00%)” |
Study limitations
Summary
ABX464-902 enrolled 59 healthy adults in the United Kingdom (24 in Part A and 35 in Part B) and has no peer-reviewed publication. The registry results, first submitted in May 2022 and posted in November 2026, give means and standard deviations only. The protocol specified geometric least squares mean ratios with 90% confidence intervals, and neither the registry nor any other public source reports them. In Part A, the posted mean caffeine AUC was 7420 hng/mL on Day 1 alone and 1560 hng/mL on Day 17 after 14 days of obefazimod, and mean Cmax was 931 and 564 ng/mL; the HRA plain-language summary states that caffeine levels “remained similar in both the presence and absence of ABX464”, and the registry gives no analysis that reconciles the two. In Part B, mean obefazimod Cmax and AUC were higher with fluvoxamine (33.4 against 23.2 ng/mL and 73.0 against 55.2 h*ng/mL), and the HRA summary states that obefazimod “may be metabolised in the same pathway as fluvoxamine”. Nine of 35 Part B participants were excluded from the pharmacokinetic analysis for vomiting and one for early withdrawal; the registry states that these exclusions “did not impact on the overall evaluation of the study objectives”. No metabolite (ABX464-N-glucuronide) result is posted, Part B used single 50 mg doses of obefazimod, and race and ethnicity were not collected.